oasis 1 oral semaglutide 50 mg obesity lancet 2023 of #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj Emerging pharmacotherapies for obesity: A

Certain thyroid conditions carry additional considerations: people with a history of medullary thyroid cancer or MEN syndrome cannot use GLP-1 medications due to FDA warnings

You also found that your TSH was low and your free T4 was high after thyroid blood testing

Side effects Common side effects of this drug are: Abdominal pain Constipation Decreased appetite Vomiting Nausea Diarrhea Precautions and Warnings Pregnancy Semaglutide safety during pregnancy is uncertain due to limited data

Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors

HCOOH formate

The SCALE Obesity trial (N=3,731) showed a mean weight loss of 8.4% at 56 weeks with liraglutide 3 mg vs